Thrombolytic Instillation for Central Venous Catheter Dysfunction and Venous Thromboembolism Risk Among Critically Ill Children
Thrombolytische Instillation bei zentralvenöser Katheterdysfunktion und Risiko für venöse Thromboembolien bei kritisch kranken Kindern
Seminars in Thrombosis and Hemostasis · 01.03.2026 · 52 (02) · 248-255
DOI: 10.1055/a-2734-3037 ↗Auf einen Blick
Bei kritisch kranken Kindern mit ZVK-Dysfunktion war der Einsatz thrombolytischer Agenzien mit HA-VTE assoziiert. In der multivariablen Analyse lag die adjustierte Odds bei 1,89.
Fragestellung
Wie häufig werden thrombolytische Agenzien zur Wiederherstellung der ZVK-Patency eingesetzt, und ist ihr Einsatz mit HA-VTE assoziiert?
Methode
Multizentrische retrospektive Kohortenstudie mit Daten aus dem Pediatric Health Information Systems database; Kinder < 18 Jahre mit CVC in 2023 an 44 Zentren.
Ergebnisse
9.822 Kinder mit 10.904 CVCs. Medianer Verschreibungsanteil 33,8 % (IQR 25–43,5 %); mediane HA-VTE-Rate 11,9 % (IQR 9,2–15,8 %). Adjustierte Odds für HA-VTE: 1,89 (95 %-KI 1,64–2,19; p < 0,001).
Schlussfolgerung der Autor:innen
Bei kritisch kranken Kindern war die Anwendung thrombolytischer Agenzien bei ZVK-Dysfunktion häufig und unabhängig mit HA-VTE assoziiert.
Kernaussagen
- 9.822 Kinder mit 10.904 CVCs
- Thrombolytikaeinsatz: median 33,8 % pro Zentrum
- HA-VTE assoziiert: adjustierte Odds 1,89
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.03.2026. Verfasst von Anthony A Sochet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Johns Hopkins All Children's Hospital, St. Pete…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Central Venous Catheters, Thrombolytic Therapy, Fibrinolytic Agents. Die Arbeit nennt 36 Literaturangaben.
Themen: Thromboseprophylaxe, Kinderkrankenpflege
Abstract (Originalsprache)
Central venous catheter (CVC) dysfunction is a common complication of indwelling CVCs for hospitalized children, often secondary to intraluminal thrombosis. We sought to characterize thrombolytic agent use for restoration of CVC patency and assess its association with hospital-acquired venous thromboembolism (HA-VTE). We performed a multicenter retrospective cohort study using the Pediatric Health Information Systems database, including critically ill children < 18 years of age with a CVC in 2023 at 44 participating centers. Exclusion criteria were VTE present on admission and thrombolytic agent (i.e., alteplase or urokinase) use for systemic or catheter-directed thrombolysis or adhesiolysis. The primary outcome was HA-VTE frequency, including deep venous thrombosis and pulmonary embolism, compared by cohorts with or without exposure to thrombolytic agents. In addition to comparative analyses, adjusted logistic regression was employed to assess the association between thrombolytic agent exposure and HA-VTE. Of 9,822 children, including 10,904 CVCs, the median participating center prescribing rate of thrombolytic agents was 33.8% (interquartile range, IQR: 25–43.5%), and the median HA-VTE rate was 11.9% (IQR: 9.2–15.8%). VTE events exhibited a bimodal age distribution (i.e., greatest among infants and adolescents) without variation by CVC type. In a multivariable conditional logistic model accounting for prothrombotic risk factors, severity of illness markers, and hospital center, thrombolytic agent use for CVC dysfunction was independently associated with HA-VTE (adjusted odds: 1.89; 95% confidence interval: 1.64–2.19, p < 0.001). Among critically ill children, thrombolytic agent use for CVC dysfunction was common and independently associated with HA-VTE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
- Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida, United States.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
- Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
- Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States.
Zitieren
APA
Sochet, A. A., Le, M. Q., Goldenberg, N. A., & Betensky, M. (2026). Thrombolytic Instillation for Central Venous Catheter Dysfunction and Venous Thromboembolism Risk Among Critically Ill Children. Seminars in Thrombosis and Hemostasis, 52(02), 248-255. https://doi.org/10.1055/a-2734-3037
Vancouver
Sochet AA, Le MQ, Goldenberg NA, Betensky M. Thrombolytic Instillation for Central Venous Catheter Dysfunction and Venous Thromboembolism Risk Among Critically Ill Children. Seminars in Thrombosis and Hemostasis. 2026;52(02):248-255. doi:10.1055/a-2734-3037
BibTeX
@article{Sochet2026,
author = {Sochet, Anthony A and Le, Minh Q and Goldenberg, Neil A and Betensky, Marisol},
title = {Thrombolytic Instillation for Central Venous Catheter Dysfunction and Venous Thromboembolism Risk Among Critically Ill Children},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {02},
pages = {248--255},
doi = {10.1055/a-2734-3037}
}
EUVIMED